ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2124

Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

Adam Savage1, Ziyuan He1, Marla Glass1, Julian Reading1, LauraKay Moss2, Marie Feser2, Vlad Tsaltskan3, Katherine Nguyen Nguyen3, Kristen Demoruelle2, kristine Kuhn4, David Boyle3, Cate Speake5, Xiao-Jun Li1, Peter Skene1, Troy Torgerson1, Tom Bumol1, V. Michael Holers6, Jane Buckner7, Gary Firestein8, kevin Deane2 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California San Diego, La Jolla, CA, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute, Seattle, WA, 6University of Colorado, Denver, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, WA, 8University of California San Diego, San Diego, CA

Meeting: ACR Convergence 2023

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), B-Lymphocyte, Biomarkers, rheumatoid arthritis, Systems-based Studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis. Rising autoantibody levels prior to clinical diagnosis suggest changing immune activity but what additional immune dysregulation may be occurring in this period is incompletely understood. The purpose of this study was to profile the immune state that accompanies elevated AAb to identify novel immune features present in individuals at-risk (ARI) to develop clinical RA.

Methods: We profiled 1463 plasma proteins, 69 peripheral blood mononuclear cell (PBMC) phenotypes, and 1,973,362 PBMCs by single-cell RNA sequencing (scRNA-seq) for a cross-sectional analysis of ARI with high levels of ACPA (anti-CCP3 IgG > 40 units) compared to healthy control individuals (HCI) (Table 1). Linear regression models were used to identify differentially expressed proteins (ARI/HCI), and to identify lineage-defining gene programs in scRNA-seq. PBMC phenotypes were selected and analyzed based on their identification in the clinical RA literature to evaluate features of clinical disease present in ARI. Wilcoxon rank sum was used to evaluate the association of B cells to AAb levels. Finally, NicheNet was used to identify putative relationships between plasma proteins and gene expression in the target cells.

Results: 314 proteins exhibited significant differential expression between ARI and HCI, including CCN1, CXCL6, CCL18, OSM, CCL5, and SERPINE1, all of which were not previously reported in ARI, as well as proteins related to B cell biology, including CXCL13, SEMA4D, LIGHT, and BAFF (Fig 1A). In addition, we found evidence for features of classifiable RA, including increased IL-1B, IL-6, TNF, CCL3, and CXCL8 plasma proteins and elevated PBMC phenotypes. Among PBMC, atypical (IgD- CD27-) B cells and Tph-like (CXCR5- PD1+) CD4T cells (Fig 1B) were significantly increased. Transcriptomic analysis (scRNA-seq) of atypical B cells, enriched in ARI, demonstrated a gene program indicative of type 2-polarized memory B cells (T2MBC), including IL4R, IL13RA1, FCER2, IGHG4, IGHE, and MEF2C (Fig 2). T2MBC abundance was correlated to RF-IgM levels (Fig 1C). NicheNet analysis identified differentially-regulated proteins CCL3 (Pearson correlation coefficient (r) = 0.093), TNFSF13B (BAFF) (r = 0.077), TNFSF14 (LIGHT) (r = 0.048), and TNF (r = 0.047), as potential regulators of the T2MBC gene program.

Conclusion: We find that otherwise healthy at-risk individuals have immune dysregulation characterized by plasma protein and PBMC phenotype changes, including some that are similar to published findings in clinical RA. In particular, the number of T2MBC B cells were elevated in ARI and we recognized a relationship to RF-IgM AAb levels. Based on NicheNet analysis, we hypothesize that circulating plasma proteins in ARI reflect the maintenance or generation of T2MBC. These data deepen our understanding of this critical at-risk state and further emphasize the tight link between the dysregulation within the B cell compartment and autoimmune disease, which could be exploited for preventative therapeutic intervention.

Supporting image 1

Supporting image 2

Figure 1. (A) Volcano plot of differential plasma protein expression between at-risk (red) and control (blue) individuals. Effect sizes and P values were determined using a linear regression model. Replicate annotations of the same protein result from repeated plate assays as part of Olink’s standard protocol. (B) PBMCs from at-risk (red) and control (blue) individuals were compared for IgD- CD27- B cells (top) and CXCR5- PD1+ CD4 T cells (Tph-like; bottom) and were tested using Wilcoxon Rank Sum with Benjamini/Yekutieli correction. Each dot represents a participant. (C) At-risk individuals were categorized by RF-IgM levels as Not detected (≤ 0.25 units) or > 0.25 units and the frequency of type 2-polarized memory B cells (T2MBC) in PMBCs was tested using Wilcoxon Rank Sum.

Supporting image 3

Figure 2. Gene expression heatmap indicating the DEGs (AUC > 0.55 or AUC < 0.45 and absolute log2 fold change > 0.1) between T2MBC and switch/unswitched memory B cells. Tbet effector are shown for comparison. Scaled normalized transcripts of pseudobulk samples are displayed.


Disclosures: A. Savage: Adaptive Biotechnologies, 3, 11, Eli Lilly, 2, 5; Z. He: Eli Lilly, 2, 5; M. Glass: Eli Lilly, 2, 5; J. Reading: None; L. Moss: None; M. Feser: None; V. Tsaltskan: None; K. Nguyen: None; K. Demoruelle: Boehringer-Ingelheim, 5, Gilead, 5, Pfizer, 5; k. Kuhn: pfizer, 5, ucb, 2; D. Boyle: None; C. Speake: None; X. Li: Eli Lilly, 5; P. Skene: Eli Lilly, 2, 5; T. Torgerson: Eli Lilly, 2, 5, Pharming Healthcare, 2, Takeda, 2; T. Bumol: Omeros Corporation, 4; V. Holers: None; J. Buckner: Bristol-Myers Squibb(BMS), 2, gentibio, 1, 10, 11, hotspot therapeutics, 2, Janssen, 2; G. Firestein: Eli Lilly, 5; k. Deane: Bristol-Myers Squibb(BMS), 1, Gilead, 5, Janssen, 5, Werfen, 1, 12, Biomarker kits; M. Gillespie: Eli Lilly, 2, 5, Novo Nordisk, 3, 12, Stock.

To cite this abstract in AMA style:

Savage A, He Z, Glass M, Reading J, Moss L, Feser M, Tsaltskan V, Nguyen K, Demoruelle K, Kuhn k, Boyle D, Speake C, Li X, Skene P, Torgerson T, Bumol T, Holers V, Buckner J, Firestein G, Deane k, Gillespie M. Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/expansion-of-atypical-b-cells-accompanies-rheumatoid-arthritis-like-immune-dysregulation-in-acpa-at-risk-individuals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-of-atypical-b-cells-accompanies-rheumatoid-arthritis-like-immune-dysregulation-in-acpa-at-risk-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology